Medicine prices announced pricing reform, the parties affected overall interpretation (1)

After a half months, I still hold the reform of the hesitation of medicines and medical services in the price formation mechanism (hereinafter referred to as the "opinion"), has finally officially released yesterday.

Previously on 9 November, the opinions of three departments check has been completed.

With the previous version of the reporter was informed that, compared to officially announce the "opinion", government regulation and market regulation, encourage research and innovation and the use of essential drugs and technology and, cost, and quality and pricing of the guiding principles of the "three in one" has not changed.

However, the lower limit of the "drug price management" and "Medicare drug prices" and originally emphasized "solved", not in the opinion referred to in the final version.

1 yaoqi medicine: the first-floor support policy

"Opinions, to boot biowaiver orderly production and competition.

On the next domestic first clone listed drugs, price references were imitation drug price is established; in the innovator drugs have not been listed in China, first of all, the price of generic medicines on the basis of its reasonable costs. And then clone the listing of drugs in accordance with the price is lower than the first clone of a certain percentage of drug prices. The same kind of generic drug manufacturers to achieve a certain number, according to the average social cost, and so develop uniform prices.

Although no suffering from adverse drug "Medicare-national treatment" price, but the first faux drug price support policies for landing, has let China's pharmaceutical companies see a loosening of hope.

Technology level, since the first faux drug as opposed to the subsequent imitation, investment in research and development production costs are high, the industry has been called for, it should be the key from the pricing policy and subsequent generics.

In March 2006, for the pharmaceutical industry, a small, casual, out of the situation, the national development and Reform Commission in the pharmaceutical pricing methods "(first version), the first drug-like" first "pricing policy, with the intention of controlling generic drug overheating problems.

This policy supports finally settles, is still at the "generics" of China, is from the policy direction of the wind has a clear guidance.

In the academic field, on the "economical" drugs is increasingly prosperous.

"Safe, effective, adequate is good," drug use and development of principles, but also make drugs developed wind direction changes, improved formulations quietly, ways and expand the indications for "improved" research and development seems to be more practical.

However, Zhejiang haizheng medicine (22.65, 0.19, 0.85%) co., Ltd. General Manager Assistant Zhu Tong Qin also told reporters that the first-to-business technology research and development capacity demands high, to achieve the first faux first is proof of the level of research and development.

This imitation of the "cake" is not easy to eat, or those with high levels of scientific and technological research and development in order to share of the enterprise.